Serum amyloid A: A biomarker for renal cancer

Anticancer Research

Volumn 32, Issue 5, 2012, Pages 1801-1804

  Fischer, Kersten ^a   Theil, Gerit ^a   Hoda, Raschid ^a   Fornara, Paolo ^a  

^a MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

Author keywords

CRP; Diagnostic marker; Kidney neoplasms; Renal cancer; Serum amyloid A

Indexed keywords

AMYLOID A PROTEIN; C REACTIVE PROTEIN; INTERLEUKIN 6;

ADVANCED CANCER; ARTICLE; CANCER STAGING; CONTROLLED STUDY; DIAGNOSTIC VALUE; HUMAN; KIDNEY CANCER; MAJOR CLINICAL STUDY; NEPHRECTOMY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SENSITIVITY AND SPECIFICITY; TUMOR LOCALIZATION;

C-REACTIVE PROTEIN; HUMANS; INTERLEUKIN-6; KIDNEY NEOPLASMS; NEOPLASM STAGING; SENSITIVITY AND SPECIFICITY; SERUM AMYLOID A PROTEIN; TUMOR MARKERS, BIOLOGICAL;

EID: 84861518617     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Stieber P and Schalhorn A: Malignes Wachstum. In: Das Laborbuch für Klinik und Praxis. Guder WG and Nolte J (eds.). München, Jena, Urban & Fischer, pp. 458, 2005.
2. Junker K, von Eggeling F, Müller J, Steiner T and Schubert J: Identifizierung von Biomarkern und therapeutischen Targets beim Nierenzellkarzinom mittels ProteinChip-Technologie. Urologe 45: 305-315, 2006.
3. Thomas L: Serum Amyloid A (SAA). In: Labor und Diagnose. Thomas L (ed.). Frankfurt/Main, TH-Books Verlagsgesellschaft mbH, pp. 1028, 2005.
4. Tsukamoto T, Kumamoto Y, Miyao N, Masumori N, Takahashi A and Yanase M: Interleukin-6 in renal cell carcinoma. J Urol 148(6): 1778-1781; discussion 1781-1782, 1992.
5. Reichle A, Grassinger J, Bross K, Wilke J, Suedhoff T, Walter B, Wieland W-F, Berand A and Andreesen R: C-Reactive protein in patients with metastatic clear cell renal carcinoma: An important biomarker for tumor-associated inflammation. Biomarker Insights 2: 87-98, 2006.
6. Crispen PL, Magera JS, Boorjian SA, Thompson RH, Lohse CM, Bkute ML, Leibovich BC and Kwon ED: Identification of potential serum markers in clear cell renal cell carcinoma. 2008 Genitourinary Cancers Symposium San Francisco, www.asco.org, abstract No 407, 2008.
7. Mata M, Lohr T, Lakshminarayanan M, Lo KH and Prabhakar U: Serum amyloid a (SAA), C-reactive protein (CRP) and IL-6 as prognostic indicators in renal cell carcinoma and prostate cancer. J Clin Oncol 22 (Suppl): 9711, 2004.
8. Jabs WJ, Busse M, Kruger S, Jocham D, Steinhoff J and Doehn C: Expression of C-reactive protein by renal cell carcinomas and unaffected surrounding renal tissue. Kidney Int 68 (5): 2103-2110, 2005. (Pubitemid 43117784)
9. Zaki MH, Nemeth J, Mount S and Trikha M: Inhibition of tumor-derived serum amyloid A (SAA) by CNTO 328, an antibody to IL-6. Proc Am Assoc Cancer Res 45: abstract #4687, 2004.
10. Manual "IMMULITE/IMMULITE 1000 IL-6", Siemens Healthcare Diagnostics, Eschborn, 2006.
11. Manual "N Latex SAA", Siemens Healthcare Diagnostics Products GmbH, Marburg, 2010.
12. Ramankulov A, Lein M, Johannsen M, Schrader M, Miller K, Loening SA and Jung K: Serum amyloid A as indicator of distant metastases but not as early tumor marker in patients with renal cell carcinoma. Cancer Lett 269: 85-92, 2008.
13. Biran H, Friedman N, Neumann L, Pras M and Shainkin-Kestenbaum R: Serum amyloid A (SAA) variations in patients with cancer: correlation with disease activity, stage, primary sire, and prognosis. J Clin Pathol 39: 794-797, 1986. (Pubitemid 16069491)
14. Chan DC, Chen CJ, Chu HC, Chang WK, Yu JC, Chen YJ, Wen LL, Huang SC, Ku CH, Liu YC and Chen JH: Evaluation of serum amyloid A as a biomarker for gastric cancer. Ann Surg Oncol 14: 84-93, 2007. (Pubitemid 44954274)
15. Glojnaric I, Casl MT, Simic D and Lukac J: Serum amyloid A protein (SAA) in colorectal carcinoma. Clin Chem Lab Med 39(2): 129-133, 2001. (Pubitemid 32318476)
16. Khan N, Cromer CJ, Campa M and Patz EF: Clinical utility of serum amyloid A and macrophage migration inhibitory factor as serum biomarkers for the detection of nonsmall cell lung carcinoma. Cancer 101(2): 379-84, 2004. (Pubitemid 38890843)
17. Yokoi K, Shih LC, Kobayashi R, Koomen J, Hawke D, Li D, Hamilton SR, Abbruzzese JL, Coombes KR and Fidler IJ: Serum amyloid A as a tumor marker in sera of nude mice with orthotopic human pancreatic cancer and in plasma of patients with pancreatic cancer. Int J Oncol 27(5): 1361-1369, 2005.
18. Moshkovskii SA, Serebryakova MV, Kuteykin-Teplyakov KB, Tikhonova OV, Goufman EI, Zgoda VG, Taranets IN, Makarov OV and Archakov AI: Ovarian cancer marker of 11.7 kDa detected by proteomics is a serum amyloid A1. Proteomics 5(14): 3790-3797, 2005. (Pubitemid 41393309)
19. Wechsel HW, Feil G, Lahme S, Zumbragel A, Petri E and Bichler KH: Control of hepatic parameters in renal cell carcinoma (RCC) by interleukin-6 (IL-6)? Anticancer Res 19(4A): 2577-2581, 1999. (Pubitemid 29392416)
20. Negrier S, Perol D, Menetrier-Caux C, Escudier B, Pallardy M, Ravaud A, Douillard JY, Chevreau C, Lasset C and Blay JY: Interleukin-6, interleukin-10, and vascular endothelial growth factor in metastatic renal cell carcinoma: prognostic value of interleukin-6 - from the Groupe Francais d'Immunotherapie. J Clin Oncol 22(12): 2371-2378, 2004. (Pubitemid 41115394)
21. Altundag O, Altundag K, Gunduz E: Interleukin-6 and C-Reactive Protein in Metastatic Renal Cell Carcinoma. J Clin Oncol 23(5): 1044, 2005. (Pubitemid 46202322)
22. Paret C, Schön Z, Szponar A and Kovacs G: Inflammatory protein serum amyloid A1 marks a subset of conventional renal cell carcinomas with fatal outcome. Eur Urol 57: 859-866, 2010.
23. Vermaat JS, van der Tweel I, Mehra N, Sleijfer S, Haanen JB, Roodhart JM, Engwegen JY, Korse CM, Langenberg MH, Kruit W, Groenewegen G, Giles RH, Schellens JH, Beijnen JH and Voest EE: Two-protein signature of novel serological markers apolipoprotein-A2 and serum amyloid alpha predicts prognosis in patients with metastatic renal cell cancer and improves the currently used prognostic survival models. Ann Oncol 21: 1472-1481, 2010.
24. Wood SL, Rogers M, Cairns DA, Paul A, Thompson D, Vasudev NS, Selby PJ and Banks RE: Assiciation of serum amyloid A protein and peptide fragments with prognosis in renal cancer. BJU 103: 101-111, 2010.
25. Tolson J, Bogumil R, Brunst E, Beck H, Elsner R, Humeny A, Kratzin H, Deeg M, Kuczyk M, Mueller GA, Mueller CA and Flad T: Serum protein profiling by SELDI mass spectrometry: detection of multiple variants of serum amyloid alpha in renal cancer patients. Lab Invest 84(7): 845-856, 2004. (Pubitemid 38833244)
26. Engwegen JYMN, Mehra N, Haanen JBAG, Bonfrer JMG, Schellen JHM, Voest EE and Beijnen JH: Validation of SELDI-TOF MS serum protein profiles for renal cell carcinoma in new populations. Lab Invest 87(2): 161-172, 2007.
27. Vermaat JS, Gerritse FL, van der Veldt AA, Roessingh WM, Niers TM, Oosting SF, Sleijfer S, Roodhart JM, Beijnen JH, Schellens JH, Gietema JA, Boven E, Richel DJ, Haanen JB and Voest EE: Validation of serum amyloid α as an indepent biomarker for progression-free and overall survival in metastatic renal cell cancer patients. Eur Urol, in press, 2012.